C4 Therapeutics, Inc. — All Filings
501 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
4/A
424B3
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
EFFECT
FWP
POS AM
POSASR
PRE 14A
S-1
S-1/A
S-1MEF
S-3
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
SUPPL
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | FORM 4 | 0001662579-25-000045 | Jun 20, 2025 | Jun 18, 2025 |
| 4 | FORM 4 | 0001662579-25-000047 | Jun 20, 2025 | Jun 18, 2025 |
| 4 | FORM 4 | 0001662579-25-000048 | Jun 20, 2025 | Jun 18, 2025 |
| 8-K | 8-K | 0001628280-25-032155 | Jun 18, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-013188 | May 15, 2025 | — |
| SCHEDULE 13G/A | — | 0000947871-25-000543 | May 15, 2025 | — |
| SCHEDULE 13G/A | — | 0000814133-25-000035 | May 7, 2025 | — |
| 10-Q | 10-Q | 0001628280-25-022866 | May 7, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0001628280-25-022864 | May 7, 2025 | — |
| DEF 14A | DEF 14A | 0001628280-25-020466 | Apr 29, 2025 | — |
| DEFA14A | DEFA14A | 0001628280-25-020467 | Apr 29, 2025 | — |
| ARS | ARS | 0001628280-25-020468 | Apr 29, 2025 | — |
| PRE 14A | PRE 14A | 0001628280-25-017927 | Apr 16, 2025 | — |
| 8-K | 8-K | 0001628280-25-017612 | Apr 14, 2025 | — |
| 4 | FORM 4 | 0001662579-25-000025 | Apr 3, 2025 | Apr 1, 2025 |
| 4 | FORM 4 | 0001662579-25-000024 | Apr 3, 2025 | Apr 1, 2025 |
| 8-K | 8-K | 0001628280-25-008429 | Feb 27, 2025 | — |
| 10-K | 10-K | 0001628280-25-008433 | Feb 27, 2025 | Dec 31, 2024 |
| S-8 | S-8 | 0001628280-25-008434 | Feb 27, 2025 | — |
| 4 | FORM 4 | 0001662579-25-000019 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | FORM 4 | 0001662579-25-000014 | Feb 18, 2025 | Feb 14, 2025 |
| 4 | FORM 4 | 0001662579-25-000020 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | FORM 4 | 0001662579-25-000015 | Feb 18, 2025 | Feb 14, 2025 |
| 4 | FORM 4 | 0001662579-25-000016 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | FORM 4 | 0001662579-25-000017 | Feb 18, 2025 | Feb 13, 2025 |
| 4 | FORM 4 | 0001662579-25-000021 | Feb 18, 2025 | Feb 14, 2025 |
| 4 | FORM 4 | 0001662579-25-000018 | Feb 18, 2025 | Feb 14, 2025 |
| 8-K | 8-K | 0001628280-25-001433 | Jan 14, 2025 | — |
| 4 | FORM 4 | 0001662579-25-000003 | Jan 3, 2025 | Jan 2, 2025 |
| 4 | FORM 4 | 0001662579-25-000004 | Jan 3, 2025 | Jan 2, 2025 |
| 8-K | 8-K | 0001628280-24-050349 | Dec 9, 2024 | — |
| 3 | FORM 3 | 0001662579-24-000107 | Nov 21, 2024 | Nov 19, 2024 |
| 4 | FORM 4 | 0001662579-24-000108 | Nov 21, 2024 | Nov 19, 2024 |
| 8-K | 8-K | 0001628280-24-048593 | Nov 20, 2024 | — |
| 144 | — | 0001972362-24-001664 | Nov 18, 2024 | — |
| 424B5 | 424B5 | 0001628280-24-048088 | Nov 15, 2024 | — |
| 424B3 | 424B3 | 0001628280-24-048091 | Nov 15, 2024 | — |
| SC 13G/A | AMENDMENT NO. 1 TO SCHEDULE 13G | 0001213900-24-098320 | Nov 14, 2024 | — |
| SC 13G/A | — | 0001493152-24-045843 | Nov 14, 2024 | — |
| SC 13G/A | C4 THERAPEUTICS, INC. | 0000902664-24-006516 | Nov 14, 2024 | — |
| SC 13G | SCHEDULE 13G | 0000947871-24-000915 | Nov 14, 2024 | — |
| SC 13G/A | — | 0000080255-24-001455 | Nov 14, 2024 | — |
| SC 13G/A | C4 THERAPEUTICS, INC. | 0000902664-24-006655 | Nov 14, 2024 | — |
| EFFECT | — | 9999999995-24-003480 | Nov 13, 2024 | — |
| SUPPL | SUPPL | 0001628280-24-047658 | Nov 13, 2024 | — |
| SUPPL | SUPPL | 0001628280-24-047659 | Nov 13, 2024 | — |
| EFFECT | — | 9999999995-24-003479 | Nov 13, 2024 | — |
| 4 | FORM 4 | 0001662579-24-000101 | Nov 12, 2024 | Nov 7, 2024 |
| 4 | FORM 4 | 0001662579-24-000102 | Nov 12, 2024 | Nov 7, 2024 |
| 4 | FORM 4 | 0001662579-24-000103 | Nov 12, 2024 | Nov 7, 2024 |